More than 200 Aussies have bought this innovative baby product this month alone: Tommee Tippee
The Tommee Tippee Ultra UV Steriliser, Dryer, and Storage Unit is a must-have for parents.
An all-in-one sterilisation solution, which is easy to use and free from chemicals has been a game-changer for those with little ones.
Its primary function is as impressive as it is essential: using ultraviolet (UV) light, it eliminates 99.9 per cent of harmful bacteria and viruses, offering peace of mind to parents seeking a safer, chemical-free method to sterilise feeding essentials.
Unlike traditional steam-based sterilisers, the Tommee Tippee Ultra UV requires no water nor heat, making it safer for delicate items and less prone to limescale buildup.
Its energy-efficient Philips UV bulb delivers up to 6,000 hours of sterilising power, ensuring long-lasting reliability while keeping operational costs low.
And it's currently 50 per cent off on Amazon Australia, normally $319, it's now $159.95.
Get in quick — we're expecting thousands of parents to snap up this epic deal.
Ready in 35 minutes
It also has incredible speed and capacity — it's able to sterilise and dry up to six bottles in just 35 minutes, a convenience that busy parents will deeply appreciate.
Once sterilised, items can remain safely stored inside the unit in its storage mode, which maintains a sterile environment and removes the need to re-sterilise bottles between uses.
Designed with versatility in mind, the steriliser accommodates most brands of baby bottles, as well as teats, pacifiers, and breast pump accessories, making it a comprehensive hygiene station for any nursery.
Feel at ease with a 12-month warranty
It also includes free delivery, a 12-month warranty, and free returns, giving parents confidence in their purchase.
The Tommee Tippee Ultra UV Steriliser really is more than a sterilising unit — it's a modern, efficient, and thoughtfully designed hygiene solution that supports healthier feeding practices with minimal effort.
For parents seeking a powerful and safe way to care for their baby's feeding gear, this product is the ultimate solution.
Shoppers have given The Tommee Tippee Ultra UV Steriliser, a 4.8-star rating on Amazon Australia's website.
'This machine makes sterilising bottles a breeze. What more could you ask for at a great price? Definitely recommended,' one impressed shopper wrote.
'Prior to purchasing the Tommee Tippee steriliser and dryer we had to manage bottles and and pumps around the clock to make sure there was a clean supply. With the steriliser and dryer, we can just throw everything in and not have to worry about taking it out, drying, storage etc,' another shopper commented.
'After bringing our newborn home, the Tommee Tippee Ultra UV Steriliser quickly became a daily essential in our kitchen. The UV technology works well and gives peace of mind knowing bottles are properly sanitised without chemicals,' a third reviewer wrote.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
3 days ago
- ABC News
Philips Electronics faces legal action for selling allegedly 'unsafe' breathing devices
The Therapeutic Goods Administration has started legal proceedings against tech giant Philips Electronics over allegations the company unlawfully sold assisted breathing devices in Australia. The devices were used by many people with sleep apnoea and were subject to a global recall in 2021 due to the risks associated with the foam used in the products. The TGA alleges 11 models of Philips mechanical ventilators, continuous positive airway pressure (CPAP) machines and bi-level positive airway pressure (BiPAP) machines sold between June 2, 2019, and October 13, 2022, were unsafe, did not perform as intended and were therefore "unlawfully supplied". It estimates 44,000 devices were sold in that period. The devices contained a polyester-based polyurethane (PE-PUR) foam to reduce noise and vibration from the machine but Philips found the foam could degrade into particles that could be inhaled or ingested by the user. "The probability of degradation, and consequential harm to the patient, was unacceptable, given the potentially serious consequences to patients," the TGA's statement of claim to the Federal Court states. The TGA alleges Philips was aware of the risks associated with the foam as early as 2015 but failed to take any action until 2021, when the devices were recalled. The TGA has submitted a range of documents it alleges demonstrate that Philips had prior knowledge of the defect, including a report from 2013 which refers to the death of a patient that year who used a particular ventilator called the Trilogy 100, which is named in the legal action. Following the global recall, Philips replaced the PE-PUR foam in the Trilogy 100 with silicone foam but by the following year it announced the new silicone foam could potentially separate from the plastic backing it was adhered to and block the air inlet. The statement of claim said this could lead to "ventilation failure or underventilation … [which] could in turn result in hypoventilation, hypoxemia, hypercapnia and asphyxia". The TGA alleges Philips did not conduct adequate risk analysis of the use of silicone foam with the adhesive. The TGA alleges exposure to the foam particles could cause short-term effects such as skin, eye and respiratory tract irritation, inflammatory responses, headaches, asthma, effects on the reproductive system and neoplasia (abnormal growth of tissue), while long-term exposure could be carcinogenic (potentially cause cancer). In a statement to the ABC, Philips Australia said since June 2021 it had conducted extensive testing with five independent, certified testing laboratories and third-party experts, and that, based on the test results, the experts concluded the devices were "not expected to result in appreciable harm to health in patients". "Philips will review the concise statement filed in the Federal Court by the Therapeutic Goods Administration and engage constructively in the required court processes," a spokesperson said. "Patient safety and quality is our number one priority, and we are focused on working closely with regulators to ensure we achieve the highest standards in the delivery of health care." The company noted the proceedings covered alleged activities in the lead-up to and during the 2021 recall but did not make allegations regarding the quality of Philips's current products. A class action against Philips lodged by consumers of the affected devices is also currently before the Federal Court in Victoria. The claim is being led by retired nurse Eva Lindbloom and aims to seek compensation for those who have suffered injury, loss or damage due to their use of the products. Last year Philips reached a $US1.1 billion ($1.7 billion) deal to settle legal action in the US over the devices. And a cross-border European class action is currently underway.
The Advertiser
4 days ago
- The Advertiser
Tech giant sued over sleep aid foam inhalation 'risk'
An alleged risk of patients breathing in or swallowing small particles of foam from degrading sleep aids has prompted the federal government to take legal action. Multinational health technology company Philips is accused of selling defective ventilators aimed at assisting with sleep apnoea and, after those products were recalled in June 2021, selling a further device which was also dangerous. In the lawsuit filed on Monday, the Therapeutic Goods Administration claims both sets of devices did not meet Australian safety standards. Devices sold prior to June 2021 contained a polyester-based polyurethane foam used for noise suppression. "There was a real risk of the (foam) degrading and then particulates being inhaled or ingested by the patient," the agency wrote in a statement. The potential harms from these devices included skin, eye and respiratory tract irritation, headaches, asthma and impacts on the reproductive system. Long-term exposure could damage or kill a patient's cells, cause genetic damage or cause cancer, the health watchdog alleges. "The probability of degradation, and consequential harm to the patient, was unacceptable, given the potentially serious consequences," the lawsuit claims. Philips did not conduct any risk analysis on the products until early 2021, the government agency says. Ten devices sold under the BiPAP, DreamStation, OmniLab and REMstar brands were recalled globally in June that year. After this date, Philips allegedly sold a further defective device, the Trilogy 100. This contained silicone foam which could become detached from its housing, obstructing the air path. Potential adverse health effects included increased carbon dioxide levels or low oxygen levels in the patient's blood. The TGA is seeking pecuniary penalties and orders that Philips pay its legal costs. A Philips spokeswoman said the lawsuit only revolved around the company's activities before and during the 2021 recall. "The proceeding does not make allegations about the quality and safety of products currently marketed in Australia by Philips," she said. The spokeswoman said extensive testing had been conducted internally as well as with five independent laboratories and third-party experts since June 2021. This testing concluded that the use of Philips sleep therapy devices presently sold on the market "is not expected to result in appreciable harm to health in patients". Philips would review the court documents filed by the TGA and engage constructively as required, she said. An alleged risk of patients breathing in or swallowing small particles of foam from degrading sleep aids has prompted the federal government to take legal action. Multinational health technology company Philips is accused of selling defective ventilators aimed at assisting with sleep apnoea and, after those products were recalled in June 2021, selling a further device which was also dangerous. In the lawsuit filed on Monday, the Therapeutic Goods Administration claims both sets of devices did not meet Australian safety standards. Devices sold prior to June 2021 contained a polyester-based polyurethane foam used for noise suppression. "There was a real risk of the (foam) degrading and then particulates being inhaled or ingested by the patient," the agency wrote in a statement. The potential harms from these devices included skin, eye and respiratory tract irritation, headaches, asthma and impacts on the reproductive system. Long-term exposure could damage or kill a patient's cells, cause genetic damage or cause cancer, the health watchdog alleges. "The probability of degradation, and consequential harm to the patient, was unacceptable, given the potentially serious consequences," the lawsuit claims. Philips did not conduct any risk analysis on the products until early 2021, the government agency says. Ten devices sold under the BiPAP, DreamStation, OmniLab and REMstar brands were recalled globally in June that year. After this date, Philips allegedly sold a further defective device, the Trilogy 100. This contained silicone foam which could become detached from its housing, obstructing the air path. Potential adverse health effects included increased carbon dioxide levels or low oxygen levels in the patient's blood. The TGA is seeking pecuniary penalties and orders that Philips pay its legal costs. A Philips spokeswoman said the lawsuit only revolved around the company's activities before and during the 2021 recall. "The proceeding does not make allegations about the quality and safety of products currently marketed in Australia by Philips," she said. The spokeswoman said extensive testing had been conducted internally as well as with five independent laboratories and third-party experts since June 2021. This testing concluded that the use of Philips sleep therapy devices presently sold on the market "is not expected to result in appreciable harm to health in patients". Philips would review the court documents filed by the TGA and engage constructively as required, she said. An alleged risk of patients breathing in or swallowing small particles of foam from degrading sleep aids has prompted the federal government to take legal action. Multinational health technology company Philips is accused of selling defective ventilators aimed at assisting with sleep apnoea and, after those products were recalled in June 2021, selling a further device which was also dangerous. In the lawsuit filed on Monday, the Therapeutic Goods Administration claims both sets of devices did not meet Australian safety standards. Devices sold prior to June 2021 contained a polyester-based polyurethane foam used for noise suppression. "There was a real risk of the (foam) degrading and then particulates being inhaled or ingested by the patient," the agency wrote in a statement. The potential harms from these devices included skin, eye and respiratory tract irritation, headaches, asthma and impacts on the reproductive system. Long-term exposure could damage or kill a patient's cells, cause genetic damage or cause cancer, the health watchdog alleges. "The probability of degradation, and consequential harm to the patient, was unacceptable, given the potentially serious consequences," the lawsuit claims. Philips did not conduct any risk analysis on the products until early 2021, the government agency says. Ten devices sold under the BiPAP, DreamStation, OmniLab and REMstar brands were recalled globally in June that year. After this date, Philips allegedly sold a further defective device, the Trilogy 100. This contained silicone foam which could become detached from its housing, obstructing the air path. Potential adverse health effects included increased carbon dioxide levels or low oxygen levels in the patient's blood. The TGA is seeking pecuniary penalties and orders that Philips pay its legal costs. A Philips spokeswoman said the lawsuit only revolved around the company's activities before and during the 2021 recall. "The proceeding does not make allegations about the quality and safety of products currently marketed in Australia by Philips," she said. The spokeswoman said extensive testing had been conducted internally as well as with five independent laboratories and third-party experts since June 2021. This testing concluded that the use of Philips sleep therapy devices presently sold on the market "is not expected to result in appreciable harm to health in patients". Philips would review the court documents filed by the TGA and engage constructively as required, she said. An alleged risk of patients breathing in or swallowing small particles of foam from degrading sleep aids has prompted the federal government to take legal action. Multinational health technology company Philips is accused of selling defective ventilators aimed at assisting with sleep apnoea and, after those products were recalled in June 2021, selling a further device which was also dangerous. In the lawsuit filed on Monday, the Therapeutic Goods Administration claims both sets of devices did not meet Australian safety standards. Devices sold prior to June 2021 contained a polyester-based polyurethane foam used for noise suppression. "There was a real risk of the (foam) degrading and then particulates being inhaled or ingested by the patient," the agency wrote in a statement. The potential harms from these devices included skin, eye and respiratory tract irritation, headaches, asthma and impacts on the reproductive system. Long-term exposure could damage or kill a patient's cells, cause genetic damage or cause cancer, the health watchdog alleges. "The probability of degradation, and consequential harm to the patient, was unacceptable, given the potentially serious consequences," the lawsuit claims. Philips did not conduct any risk analysis on the products until early 2021, the government agency says. Ten devices sold under the BiPAP, DreamStation, OmniLab and REMstar brands were recalled globally in June that year. After this date, Philips allegedly sold a further defective device, the Trilogy 100. This contained silicone foam which could become detached from its housing, obstructing the air path. Potential adverse health effects included increased carbon dioxide levels or low oxygen levels in the patient's blood. The TGA is seeking pecuniary penalties and orders that Philips pay its legal costs. A Philips spokeswoman said the lawsuit only revolved around the company's activities before and during the 2021 recall. "The proceeding does not make allegations about the quality and safety of products currently marketed in Australia by Philips," she said. The spokeswoman said extensive testing had been conducted internally as well as with five independent laboratories and third-party experts since June 2021. This testing concluded that the use of Philips sleep therapy devices presently sold on the market "is not expected to result in appreciable harm to health in patients". Philips would review the court documents filed by the TGA and engage constructively as required, she said.
9 News
4 days ago
- 9 News
Tech giant sued over risk from sleeping aids
Your web browser is no longer supported. To improve your experience update it here An alleged risk of patients breathing in or swallowing small particles of foam from degrading sleep aids has prompted the federal government to take legal action. Multinational health technology company Philips is accused of selling defective ventilators aimed at assisting with sleep apnoea and, after those products were recalled in June 2021, selling a further device which was also dangerous. In the lawsuit filed yesterday, the Therapeutic Goods Administration claims both sets of devices did not meet Australian safety standards. An alleged risk of patients breathing in or swallowing small particles of foam from degrading sleep aids has prompted the federal government to take legal action. (Getty Images/iStockphoto) Devices sold prior to June 2021 contained a polyester-based polyurethane foam used for noise suppression. "There was a real risk of the (foam) degrading and then particulates being inhaled or ingested by the patient," the agency wrote in a statement. The potential harms from these devices included skin, eye and respiratory tract irritation, headaches, asthma and impacts on the reproductive system. Long-term exposure could damage or kill a patient's cells, cause genetic damage or cause cancer, the health watchdog alleges. "The probability of degradation, and consequential harm to the patient, was unacceptable, given the potentially serious consequences," the lawsuit claims. Philips did not conduct any risk analysis on the products until early 2021, the government agency says. Ten devices sold under the BiPAP, DreamStation, OmniLab and REMstar brands were recalled globally in June that year. After this date, Philips allegedly sold a further defective device, the Trilogy 100. This contained silicone foam which could become detached from its housing, obstructing the air path. Potential adverse health effects included increased carbon dioxide levels or low oxygen levels in the patient's blood. The TGA is seeking pecuniary penalties and orders that Philips pay its legal costs. A Philips spokeswoman said the lawsuit only revolved around the company's activities before and during the 2021 recall. "The proceeding does not make allegations about the quality and safety of products currently marketed in Australia by Philips," she said. The spokeswoman said extensive testing had been conducted internally as well as with five independent laboratories and third-party experts since June 2021. This testing concluded that the use of Philips sleep therapy devices presently sold on the market "is not expected to result in appreciable harm to health in patients". Philips would review the court documents filed by the TGA and engage constructively as required, she said. national Australia courts Sydney New South Wales Technology Tech CONTACT US
